Percent of adolescents 13-17 years who have received the specified number of doses of the vaccine by the last day of the quarter

- 1:1:2 series¥ includes >=1 dose of Td or Tdap vaccine, >=1 dose of meningococcal conjugate (MCV4) vaccine and up-to-date with either 2 or 3 doses of human papillomavirus (HPV) vaccine
- ¥: rate for >=2 doses of MCV4 vaccine was assessed only for adolescents 16-17 years of age.
- €: rate for series start and series up-to-date with Meningococcal B vaccine was assessed only for adolescents 16-17 years of age.

Data Source: North Dakota Immunization Information System (NDIIS)